🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the infection, according to researchers.

An International Challenge

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million infections per year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in recent days for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which uses an injection and a pill. The study enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Doctors on the front lines have shared positive views. The availability of a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the infection for people and to halt the transmission of extremely resistant gonorrhoea around the world.